Bioprofiling and vaccine development for Zika virus

Area of Science:

• Virology
• Public Health
• Immunology

Background:

• Zika virus (ZIKV) is a global health concern linked to severe congenital abnormalities like microcephaly and Guillain-Barré Syndrome (GBS).
• The World Health Organization (WHO) declared ZIKV a Public Health Emergency of International Concern (PHEIC).
• Antibody-dependent enhancement (ADE) complicates ZIKV vaccine and therapeutic development.

Purpose of the Study:

• To review ZIKV-associated risks, including transmission dynamics, viral architecture, and cellular entry.
• To propose evidence-based prevention and management strategies for ZIKV infection.

Main Methods:

• Review of existing literature on ZIKV transmission, viral structure, and cell entry mechanisms.
• Analysis of epidemiological data linking ZIKV to congenital abnormalities and GBS.
• Examination of the role of ADE in ZIKV pathogenesis and vaccine development.

Main Results:

• ZIKV transmission occurs through various routes, posing risks to pregnant women and adults.
• Viral architecture and cellular entry mechanisms are key factors in ZIKV pathogenesis.
• ADE significantly hinders the development of effective vaccines and therapies.

Conclusions:

• Despite research progress, no approved vaccines or therapies for ZIKV currently exist.
• Understanding ZIKV transmission, entry, and ADE is crucial for developing effective countermeasures.
• Evidence-based prevention and management strategies are essential for mitigating ZIKV's global health impact.